STRO

Sutro Biopharma, Inc.

10.17

USD

-0.44

-4.15%

Nov 10, 15:59 UTC -5

Closed

After-Market

10.21

+0.04

+0.44%

Sutro Biopharma, Inc. (STRO) Earnings

STRO Earnings Reports

Positive Surprise Ratio

STRO beat 15 of 32 last estimates.

47%

Next Report

Tomorrow

Date of Next Report

Nov 11, 2026

Estimate for Q3 26 (Revenue/ EPS)

$10.55M

-$1.94

Implied change from Q2 26 (Revenue/ EPS)

+7.21%

-16.74%

Implied change from Q3 25 (Revenue/ EPS)

+8.82%

-71.04%

Sutro Biopharma, Inc. earnings per share and revenue

On Aug 12, 2026, STRO reported earnings of -2.33 USD per share (EPS) for Q2 26, missing the estimate of -2.23 USD, resulting in a -4.12% surprise. Revenue reached 9.84 million, compared to an expected 13.31 million, with a -26.07% difference. The market reacted with a -14.94% price change (close before vs. close after earnings).

Looking ahead to Q3 26, 8 analysts forecast an EPS of -1.94 USD, with revenue projected to reach 10.55 million USD, implying an decrease of -16.74% EPS, and increase of 7.21% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

FAQ

What were Sutro Biopharma, Inc.'s earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Sutro Biopharma, Inc. reported EPS of -$2.33, missing estimates by -4.12%, and revenue of $9.84M, -26.07% below expectations.

How did the market react to Sutro Biopharma, Inc.'s Q2 2026 earnings?

The stock price moved down -14.94%, changed from $25.04 before the earnings release to $21.30 the day after.

When is Sutro Biopharma, Inc. expected to report next?

The next earning report is scheduled for Nov 11, 2026.

What are the forecasts for Sutro Biopharma, Inc.'s next earnings report?

Based on 8 analysts, Sutro Biopharma, Inc. is expected to report EPS of -$1.94 and revenue of $10.55M for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.